Topic

All

4
Dec
2022

Hot Topics in Biopharma: Initial Impact of Digital, Data Dilemmas in Clinical Studies, and the Search for ‘New Normal’

For today: topics relevant to many drug developers (and others): The initial impact of digital The dilemma of data collection in early clinical studies The elusive search for “new normal” ways of working Initial impact of digital in biopharma The sexy promise of digital/data/AI in biopharma was that emerging digital technologies were going to solve our most important and vexing...
Read More
15
Nov
2022

Team Julie: Fighting Back Against Glioblastoma

Thirty-seven years ago, I met a lovely and talented young woman while we were both pursuing our PhDs. We were married during our last year in graduate school, and have spent every day since raising a family; working in STEM-Medicine careers; and engaging with our communities. We had just retired in 2019 and begun making plans to travel and enjoy...
Read More
14
Nov
2022

ICYMI – Recommended Reading and Listening for Biotech Innovators

Searching for a good listen or an interesting read? Here are my latest suggestions. Everything is awesome! Looking for something thoughtful and uplifting? A great place to start is this recent interview with tech VC Marc Andreessen, who discusses, persuasively, why he is still so optimistic about technology. Particularly useful: Andreessen’s ability to contextualize the evolution of technology, including the...
Read More
7
Nov
2022

Delivery of Genetic Medicines: Shehnaaz Suliman on The Long Run

Today’s guest on The Long Run is Shehnaaz Suliman. Shehnaaz is the CEO of Menlo Park, California-based ReCode Therapeutics. Recode is working on lipid nanoparticles to improve the delivery of genetic medicines. These little packages have made it possible to deliver billions of mRNA COVID vaccines in people’s arms, saving millions of lives. It’s been two decades of hard work....
Read More
28
Oct
2022

It Ain’t Over Til It’s Over

If you’re still curious about COVID-19, then good for you. Many people apparently have stopped paying attention, but COVID-19 remains a relevant topic. Here’s where things stand this fall with viral variants and our countermeasures. We are starting a period of the Omicron epidemic in which the numbering is no longer B1, B2, B3, B4, B5. We’re into the Omicron...
Read More
27
Oct
2022

You Have Chosen … Poorly: Why Drug Developers Make Bad Decisions

Drug development remains an incredibly expensive endeavor. Much of the cost can be attributed to late-stage clinical trial failures.  The burden is borne first and foremost by clinical trial participants who aren’t helped by the experimental medicine. It also significantly impacts the companies sponsoring these studies. Everyone would like to improve the chances that a novel medicine that advances into...
Read More
26
Oct
2022

Biotech Executives Call for Action on Reproductive Health Rights

Dear Friends and Biopharma colleagues,  The rapidly approaching midterm elections carry the potential to dramatically reshape the political landscape in myriad ways. The importance of the US Supreme Court’s Dobbs decision in June, overturning Roe v. Wade, looms large.  At this critical time, we must be clear that Dobbs was about more than abortion.  With the decision to eliminate a...
Read More
11
Oct
2022

Protein Degraders For Outside the Cell: Aetna Wun Trombley on The Long Run

Today’s guest on The Long Run is Aetna Wun Trombley. Aetna is the CEO of South San Francisco-based Lycia Therapeutics. Many in biotech know about targeted protein degraders. Arvinas and Kymera Therapeutics are a couple of the well-known companies that make these drugs which work to inhibit intracellular proteins. This approach has drawn a lot of excitement because it can...
Read More
1 2 3 62